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Figure 1. IIF using 1 mol/L NaCl split normal human skin as
a substrate.
autoantigen of LABD by immunoblot studies in only a few
reports [4, 5].
The major target antigen in LABD is LAD-1, a protein of
120 k-Da, which is a proteolytic fragment of the extracellu-
lar domain of BP180 as a result of its cleavage on the surface
of keratinocytes by the action of an enzyme. This enzyme
belongs to the family of ADAMTS (A disintegrin and A
metalloprotease). The other well known antigen is a 97 k-
Da protein which is a fragment of the 120 k-Da protein [6].
In our immunoblot analysis, we also found autoantibodies
reactive with a 97 k-Da protein, but less reactive.
In this case, we report the novel finding of an IgA directed
against a protein of 200 k-Da located on the epidermis. Zone
et al. also found a band at 200 k-Da in patient’s serum with
LABD [4]. In fact, this 200 k-Da band, reactive with whole
serum, was not present when the purified antibody was used.
This suggested that the antibody that bound to this 200 k-
Da band was not purified by the immunoaffinity process
using human BMZ. These results suggested that the pres-
ence of those antibodies may be just an epiphenomenon.
However, Fujimoto et al. [6] showed that circulating IgA
autoantibodies to 200 and 280 k-Da antigens were detected
in an LABD patient’s serum by immunoblot analysis using
extracts from normal human epidermis and human epi-
dermal keratinocytes. These two antibodies also reacted
with the epidermal side of 1 mol/L NaCl split skin on IIF
microscopy and bound to hemidesmosomes as determined
by immunoperoxydase electronic microcopy. Our results
may also suggest the presence of 200 k-Da hemidesmo-
somal proteins as target antigens in linear IgA disease.
Our observation supports the contention that LAD is a het-
erogeneous disease. Further studies need to investigate if
these antibodies directed toward a protein of 200 k-Da are
pathogenic, where this 200 k-Da protein is situated and
which protein of the BMZ is implicated in such cases. 
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Sjögren-Larsson syndrome due to a novel
mutation in the FALDH gene
Sjögren-Larsson syndrome (SLS) is a rare autosomal reces-
sive disorder characterized by the presence of congenital
ichthyosis, spastic diplegia or tetraplegia and mild to mode-
rate mental retardation. SLS is caused by mutations in the
ALDH3A2 gene, which encodes for fatty aldehyde dehy-
drogenase (FALDH) [1-3], an enzyme that catalyzes the
oxidation of medium- and long-chain aliphatic aldehydes
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[3-5]. The genotype of SLS patients varies considerably,
with many private mutations in individual patients [4, 5].
We report a 2.5-year-old girl presenting with a history of
generalized extremely dry and scaly skin since birth. Her
mental and motor development was also delayed; she had
spastic diplegia of the legs and expressed herself only in
monosyllables. She had been born at gestational week 35,
after a normal pregnancy with no antenatal or perinatal
complications. There was no history suggestive of a
colloidion membrane at the time of birth. Family history
showed consanguinity, the parents were second degree
cousins, but there were no other relatives with SLS.
Gradually the skin lesions worsened, becoming thicker,
especially over the flexures, with some lichenified
hyperkeratosis (ﬁgure 1). The lesions were very pruritic.
Scaling and hyperlinearity of palms and soles was present.
Ophthalmological and otorhinolaryngological examination
was normal.
Magnetic resonance imaging of the brain revealed
unmyelinated white matter, and the proton spectroscopy
demonstrated an abnormal white matter peak at 1.3 ppm.
Histopathologic examination showed orthohyperkeratosis,
acanthosis and papillomatosis. Genetic analysis of the
patient detected a delection of thymidine at position 805
of the exon 6 [c.805delT (p.Tyr269fsX5)] of the FALDH
gene in a homozygous state. The same mutation was found
in heterozygous state in both parents. This mutation has
not been previously reported and functional analysis was
not performed. However, as it introduces a premature stop
condon, it is predicted to cause either a reduced expression
of the mRNA or a truncated protein, with consequent reduc-
tion of the amount of enzyme produced or loss of enzymatic
function, respectively.
SLS is a chronic disabling neurocutaneous disease with
autosomal recessive inheritance that was described in detail
Figure 1. Generalized dry and scaly skin.
by two Swedish psychiatrists, Sjögren and Larsson, in 1957
[1]. It is caused by mutations in the ALDH3A2 gene, how-
ever the relationship between the genotype and the clini-
cal phenotype of SLS has been difficult to establish [4].
The consequent accumulation of fatty aldehyde precursors,
including fatty alcohols, caused by the FALDH deficiency,
is postulated to affect the normal formation of multi-
lamellar membranes in the stratum corneum and myelin,
and to result in the symptoms [5].
The neurological features of SLS appear in the first years of
life and then seem to stabilize [5]. Cerebral proton magnetic
resonance spectroscopy in patients with SLS demonstrates
an abnormal white matter peak at 1.3 ppm [6], consistent
with long-chain fatty alcohol accumulation and coincides
with retarded myelination [5].
The diagnosis of SLS is invariably delayed, similarly
to other rare genodermatosis. On clinical grounds the
diagnosis should be suspected in infants with congenital
ichthyosis, especially with emerging neurological features.
The ichthyosis is usually the first signal that brings the
patient to medical attention, emphasizing the role of the
dermatologist in the diagnosis. Unlike most other forms of
ichthyosis, it has a disturbing pruritic character and, as in
our case, patients tend to be born preterm.
To our knowledge, the mutation of our patient has not been
previously reported, supporting the rich mutational hetero-
geneity associated with this syndrome. 
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